卡马西平、奥卡西平与艾司利卡西平HLA基因检测指南
该指南由英国CERSI-PGx制定,针对卡马西平、奥卡西平与艾司利卡西平用药前HLA基因检测提出推荐。任何未治疗或用药不足3个月的患者,无论 ancestry 或适应症,均应检测HLA-B*15:02、HLA-B*15:11和HLA-A*31:01以降低超敏反应风险。HLA-B*15:02阳性者应避免使用这三类药物;HLA-A*31:01或HLA-B*15:11阳性者若有替代方案也应避免。
要点
- 用药前或用药不足3个月者应检测HLA-B*15:02、HLA-B*15:11和HLA-A*31:01。
- HLA-B*15:02阳性者应避免卡马西平、奥卡西平与艾司利卡西平。
- HLA-A*31:01或HLA-B*15:11阳性者若有替代方案应避免使用。
核心结论
- 对拟用或用药不足3个月的卡马西平、奥卡西平、艾司利卡西平患者应检测相关HLA等位基因以降低超敏反应风险。
- HLA-B*15:02阳性者应避免使用卡马西平、奥卡西平与艾司利卡西平。
- HLA-A*31:01或HLA-B*15:11阳性者若有替代方案也应避免使用这三类药物。
研究设计与样本
- 本指南由英国CERSI-PGx制定,基于最新证据并与其他国际药物基因组学处方指南兼容。
主要发现
- 卡马西平、奥卡西平与艾司利卡西平可导致免疫介导的超敏反应,通常累及皮肤,严重程度不一,也可影响肝脏及其他器官系统。
- HLA-B*15:02、HLA-B*15:11和HLA-A*31:01是这些超敏反应的已知易感因素。
关键数值与推荐
- 任何未治疗或用药不足3个月的患者,无论 ancestry 或适应症,均应检测所有临床相关HLA等位基因。
- HLA-B*15:02阳性者应避免卡马西平、奥卡西平与艾司利卡西平。
- HLA-A*31:01或HLA-B*15:11阳性者若有替代方案应避免使用这三类药物。
- 无法使用替代方案时,应在仔细权衡利弊后开始治疗,加强监测并告知患者出现皮疹时的应对措施。
临床怎么用
- 处方卡马西平、奥卡西平或艾司利卡西平前应检测HLA-B*15:02、HLA-B*15:11和HLA-A*31:01。
- HLA-B*15:02阳性者避免使用这三类药物,HLA-A*31:01或HLA-B*15:11阳性者优先选用替代方案。
- 无法替代时需权衡利弊、加强监测并教育患者皮疹应对措施。
局限性
- 本指南基于最新证据但无法涵盖所有个体化因素,处方者需全面评估每位患者的风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune-mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity. The liver and other organ systems can also be affected. The HLA alleles, HLA-B*15:02, HLA-B*15:11 and HLA-A*31:01, are known predisposing factors for these hypersensitivity reactions. Any treatment-naïve patient, regardless of ancestry or indication for treatment, who is about to be prescribed carbamazepine, oxcarbazepine or eslicarbazepine, or has been on these drugs for less than 3 months, should undergo pharmacogenetic testing to identify all clinically relevant HLA alleles to reduce the risk of hypersensitivity reactions. Carbamazepine, oxcarbazepine and eslicarbazepine should be avoided in HLA-B*15:02-positive patients. These drugs should also be avoided in patients positive for HLA-A*31:01 or HLA-B*15:11 if an alternative is possible. Where it is not possible to use an alternative, treatment should only be commenced after careful consideration of the benefits and risks, with increased monitoring and advising patients on appropriate action to take if a skin rash occurs. Our guideline is compatible with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk-benefit profile, ensuring that therapy is optimised to maximise benefits whilst minimising potential harms.
引用
- Galloway L, Dello Russo C, Bass N, et al. HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2026. PMID: 42002301. doi:10.1002/bcp.70559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。